CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), specifically those targeting PD-1 or programmed death-ligand 1 (PD-L1), have rapidly transformed the treatment paradigm for non-small cell lung cancer (NSCLC).